A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. Takeda Pharmacuetical Co…
View full post on Diabetes News From Medical News Today
New comments